Antibe Therapeutics Inc. Price Chart
Antibe Therapeutics Inc. 4B70.F Financial and Trading Overview
| Antibe Therapeutics Inc. stock price | 0.19 EUR |
| Previous Close | 0.33 EUR |
| Open | 0.33 EUR |
| Bid | 0.33 EUR x N/A |
| Ask | 0.35 EUR x N/A |
| Day's Range | 0.33 - 0.33 EUR |
| 52 Week Range | 0.3 - 0.53 EUR |
| Volume | 2K EUR |
| Avg. Volume | 59 EUR |
| Market Cap | 17.13M EUR |
| Beta (5Y Monthly) | 0.201058 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.393 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4B70.F Valuation Measures
| Enterprise Value | -24410668 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.40000004 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.088 |
Trading Information
Antibe Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | 0.201058 |
| 52-Week Change | -24.77% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.53 EUR |
| 52 Week Low | 0.3 EUR |
| 50-Day Moving Average | 0.35 EUR |
| 200-Day Moving Average | 0.37 EUR |
4B70.F Share Statistics
| Avg. Volume (3 month) | 59 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 51.63M |
| Float | 49.31M |
| Short Ratio | N/A |
| % Held by Insiders | 7.79% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 0.1:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.86% |
| Return on Equity (ttm) | -40.84% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -22442750 EUR |
| Net Income Avi to Common (ttm) | -21341000 EUR |
| Diluted EPS (ttm) | -0.393 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 42.36M EUR |
| Total Cash Per Share (mrq) | 0.81 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 15.706 |
| Book Value Per Share (mrq) | 0.825 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16690000 EUR |
| Levered Free Cash Flow (ttm) | -7813250 EUR |
Profile of Antibe Therapeutics Inc.
| Country | Germany |
| State | ON |
| City | Toronto |
| Address | 15 Prince Arthur Avenue |
| ZIP | M5R 1B2 |
| Phone | N/A |
| Website | https://www.antibethera.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 37 |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
Q&A For Antibe Therapeutics Inc. Stock
What is a current 4B70.F stock price?
Antibe Therapeutics Inc. 4B70.F stock price today per share is 0.19 EUR.
How to purchase Antibe Therapeutics Inc. stock?
You can buy 4B70.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Antibe Therapeutics Inc.?
The stock symbol or ticker of Antibe Therapeutics Inc. is 4B70.F.
How many shares does Antibe Therapeutics Inc. have in circulation?
The max supply of Antibe Therapeutics Inc. shares is 51.9M.
What is Antibe Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Antibe Therapeutics Inc. PE Ratio is now.
What was Antibe Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Antibe Therapeutics Inc. EPS is -0.393 EUR over the trailing 12 months.